Diabetic Nephropathy Market

Market Overview: 

The 7 major diabetic nephropathy markets reached a value of US$ 9,717.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14,572.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The diabetic nephropathy market has been comprehensively analyzed in IMARC's new report titled "Diabetic Nephropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic nephropathy is a serious complication of diabetes that affects the kidneys. It occurs when high blood sugar levels over time damage the blood vessels and filtering units (glomeruli) in the kidneys, leading to a decrease in kidney function. Early symptoms of this ailment may not be noticeable, but as the disease progresses, patients may experience swelling in the legs, ankles, feet, or face, fatigue, worsening blood pressure control, nausea, vomiting, loss of appetite, difficulty sleeping, etc. Numerous other common indications associated with the illness include protein in the urine, confusion, shortness of breath, persistent itching, an increased need to urinate, etc. The diagnosis of diabetic nephropathy typically requires routine screening tests, such as albumin/creatinine ratio, glomerular filtration rate, urinary albumin test, etc. The healthcare provider may also perform various imaging studies, including X-rays and ultrasounds, to determine the structure and size of the kidney. In some cases, a biopsy is recommended, which involves the removal of small pieces of kidney tissue for medical examination.

The increasing prevalence of high blood pressure and diabetes, which directly damage blood vessels as well as other kidney cells, is primarily driving the diabetic nephropathy market. In addition to this, the rising incidences of numerous associated risk factors, such as obesity, high blood cholesterol, smoking, family history, etc., are also bolstering the market growth. Furthermore, the inflating utilization of effective medications, including angiotensin 2 receptor blockers and glucagon-like peptide-1 (GLP-1) receptor agonists, to help normalize high blood pressure and lower blood sugar levels is acting as another significant growth-inducing factor. Additionally, various government bodies and non-governmental organizations are taking initiatives to create awareness as well as improve access to educational programs, including behavioral counseling for individuals with diabetic nephropathy. This, in turn, is also propelling the market growth. Moreover, the emerging popularity of mesenchymal stem cell therapy for treating the condition since it prevents dialysis, eliminates the need for insulin injections, and lowers the risk of disease progression in patients is expected to drive the diabetic nephropathy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic nephropathy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for diabetic nephropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic nephropathy market in any manner.

Key Highlights:

• Diabetic nephropathy rarely occurs before 10 years of type 1 diabetes mellitus.
• Approximately 3% of newly diagnosed patients with type 2 diabetes mellitus have overt nephropathy.
• The peak incidence (3% per year) is typically seen in those who have had diabetes for 10-20 years, following which the rate gradually drops.
• The chance of developing diabetic nephropathy is low in a normoalbuminuric patient with diabetes for more than 30 years.
• Diabetic nephropathy is more severe and common among Blacks (three to six times more common than in Whites), Mexican Americans, and Pima Indians with type 2 diabetes.

Drugs:

Invokana (Canagliflozin) is a prescription drug intended to lower the risk of hospitalization for heart failure in persons with type 2 diabetes mellitus and diabetic kidney disease (nephropathy) with a specific level of protein in the urine. Invokana is an SGLT2 inhibitor that increases the amount of glucose removed from the bloodstream and excreted in urine.

INV-202 is a small molecule CB1 receptor blocker being developed to treat a variety of cardiometabolic diseases, including diabetic kidney disease. It is specifically developed to selectively block CB1 receptors in peripheral tissues such as the kidneys, GI tract, liver, pancreas, adipose tissues, muscles, lungs, and other organs.

Bardoxolone methyl is a low-molecular molecule that activates the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor involved in the body's stress response. This compound's anti-oxidative stress and anti-inflammatory properties have the potential to improve renal function. In the phase 2 clinical investigation conducted in Japan (the TSUBAKI study), treatment of bardoxolone methyl resulted in a significant improvement in glomerular filtration rate (kidney function) as determined by the inulin clearance method.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the diabetic nephropathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the diabetic nephropathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current diabetic nephropathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the diabetic nephropathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the diabetic nephropathy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the diabetic nephropathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of diabetic nephropathy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of diabetic nephropathy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of diabetic nephropathy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with diabetic nephropathy across the seven major markets?
• What is the size of the diabetic nephropathy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of diabetic nephropathy?
• What will be the growth rate of patients across the seven major markets?
   

Diabetic Nephropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for diabetic nephropathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic nephropathy market?
• What are the key regulatory events related to the diabetic nephropathy market?
• What is the structure of clinical trial landscape by status related to the diabetic nephropathy market?
• What is the structure of clinical trial landscape by phase related to the diabetic nephropathy market?
• What is the structure of clinical trial landscape by route of administration related to the diabetic nephropathy market?